Amgen Inc Drug Patent Portfolio
Amgen Inc owns 3 orange book drugs protected by 28 US patents Given below is the list of Amgen Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11426404 | Dosing of KRAS inhibitor for treatment of cancers | 15 Sep, 2040 | Active |
| US11236091 | Solid state forms | 20 May, 2040 | Active |
| US11827635 | Solid state forms | 20 May, 2040 | Active |
| US12280056 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | 18 Nov, 2039 | Active |
| US10519146 | KRAS G12C inhibitors and methods of using the same | 21 May, 2038 | Active |
| US10092541 | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | 29 Nov, 2034 | Active |
| US9872854 | Methods for the treatment of psoriatic arthritis using apremilast | 29 Nov, 2034 | Active |
| US10092541 | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | 29 May, 2034 | Active |
| US9872854 | Methods for the treatment of psoriatic arthritis using apremilast | 29 May, 2034 | Active |
| US7427638 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof | 16 Aug, 2028 | Active |
| US7427638 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof | 16 Feb, 2028 | Active |
| US7867996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 12 Jun, 2027 | Active |
| US7867996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 12 Dec, 2026 | Active |
| US7361649 | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 22 Aug, 2026 | Active |
| US7361650 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 22 Aug, 2026 | Active |
| US7879842 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 22 Aug, 2026 | Active |
| US7361649 | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 22 Feb, 2026 | Active |
| US7361650 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 22 Feb, 2026 | Active |
| US7879842 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | 22 Feb, 2026 | Active |
| US7893101 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof | 09 Dec, 2023 | Expired |
| US6962940 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | 19 Mar, 2023 | Expired |
| US7208516 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | 19 Mar, 2023 | Expired |
| US7659302 | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione | 19 Mar, 2023 | Expired |
| US8455536 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione | 19 Mar, 2023 | Expired |
| US8802717 | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione | 19 Mar, 2023 | Expired |
| US9018243 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof | 19 Mar, 2023 | Expired |
| US9724330 | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | 19 Mar, 2023 | Expired |
| US6020358 | Substituted phenethylsulfones and method of reducing TNFα levels | 30 Oct, 2018 | Expired |
Latest Legal Activities on Amgen Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amgen Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 29 Nov, 2023 | US11827635 |
| Recordation of Patent eGrant | 28 Nov, 2023 | US11827635 |
| Patent eGrant Notification | 28 Nov, 2023 | US11827635 |
| Mail Patent eGrant Notification | 28 Nov, 2023 | US11827635 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Nov, 2023 | US11827635 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Nov, 2023 | US11827635 |
|
Email Notification
Critical
| 09 Nov, 2023 | US11827635 |
|
Issue Notification Mailed
Critical
| 08 Nov, 2023 | US11827635 |
|
Application Is Considered Ready for Issue
Critical
| 25 Oct, 2023 | US11827635 |
| Dispatch to FDC | 25 Oct, 2023 | US11827635 |
|
Issue Fee Payment Received
Critical
| 23 Oct, 2023 | US11827635 |
|
Issue Fee Payment Verified
Critical
| 23 Oct, 2023 | US11827635 |
|
Electronic Review
Critical
| 09 Aug, 2023 | US11827635 |
|
Email Notification
Critical
| 09 Aug, 2023 | US11827635 |
|
Mail Notice of Allowance
Critical
| 09 Aug, 2023 | US11827635 |
Amgen Inc Drug Patents' Oppositions Filed in EPO
Amgen Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 26, 2010, by Ratiopharm Gmbh. This opposition was filed on patent number EP03721414A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP10162667A | Mar, 2020 | Galenicum Health S.L.U. | Revoked |
| EP10162667A | Feb, 2020 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Revoked |
| EP10162667A | Feb, 2020 | Zentiva k.s. | Revoked |
| EP10162667A | Feb, 2020 | Hexal AG | Revoked |
| EP10162667A | Feb, 2020 | Wuesthoff & Wuesthoff Patentanwälte PartG mbB | Revoked |
| EP15177140A | Oct, 2019 | KRKA, d.d., Novo mesto | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Zentiva k.s. | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Cipla Ltd | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Dr. Reddy's Laboratories Limited | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Hexal AG | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Química Sintética, S.A. | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Generics (UK) Ltd | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Granted and Under Opposition |
| EP15177140A | Oct, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10162653A | Feb, 2018 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Revoked |
| EP09003138A | Jul, 2017 | Accord Healthcare | Revoked |
| EP03721414A | May, 2010 | Ratiopharm GmbH | Revoked |
Amgen Inc's Family Patents
Amgen Inc drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 17.7% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Amgen Inc Drug List
Given below is the complete list of Amgen Inc's drugs and the patents protecting them.
1. Corlanor
Corlanor is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7867996
(Pediatric)
| γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
12 Jun, 2027
(1 year, 11 months from now)
| Active |
| US7867996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
12 Dec, 2026
(1 year, 5 months from now)
| Active |
| US7361649
(Pediatric)
| β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Aug, 2026
(1 year, 1 month from now)
| Active |
| US7361650
(Pediatric)
| γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Aug, 2026
(1 year, 1 month from now)
| Active |
| US7879842
(Pediatric)
| Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Aug, 2026
(1 year, 1 month from now)
| Active |
| US7361649 | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Feb, 2026
(7 months from now)
| Active |
| US7361650 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Feb, 2026
(7 months from now)
| Active |
| US7879842 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
22 Feb, 2026
(7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Corlanor's drug page
2. Lumakras
Lumakras is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11426404 | Dosing of KRAS inhibitor for treatment of cancers |
15 Sep, 2040
(15 years from now)
| Active |
| US11236091 | Solid state forms |
20 May, 2040
(14 years from now)
| Active |
| US11827635 | Solid state forms |
20 May, 2040
(14 years from now)
| Active |
| US12280056 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
18 Nov, 2039
(14 years from now)
| Active |
| US10519146 | KRAS G12C inhibitors and methods of using the same |
21 May, 2038
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumakras's drug page
3. Otezla
Otezla is protected by 15 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10092541
(Pediatric)
| Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
29 Nov, 2034
(9 years from now)
| Active |
| US9872854
(Pediatric)
| Methods for the treatment of psoriatic arthritis using apremilast |
29 Nov, 2034
(9 years from now)
| Active |
| US10092541 | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
29 May, 2034
(8 years from now)
| Active |
| US9872854 | Methods for the treatment of psoriatic arthritis using apremilast |
29 May, 2034
(8 years from now)
| Active |
| US7427638
(Pediatric)
| (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
16 Aug, 2028
(3 years from now)
| Active |
| US7427638 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
16 Feb, 2028
(2 years from now)
| Active |
| US7893101 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
09 Dec, 2023
(1 year, 6 months ago)
| Expired |
| US6962940 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
19 Mar, 2023
(2 years ago)
| Expired |
| US7208516 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
19 Mar, 2023
(2 years ago)
| Expired |
| US7659302 | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
19 Mar, 2023
(2 years ago)
| Expired |
| US8455536 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
19 Mar, 2023
(2 years ago)
| Expired |
| US8802717 | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
19 Mar, 2023
(2 years ago)
| Expired |
| US9018243 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
19 Mar, 2023
(2 years ago)
| Expired |
| US9724330 | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
19 Mar, 2023
(2 years ago)
| Expired |
| US6020358 | Substituted phenethylsulfones and method of reducing TNFα levels |
30 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Otezla's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List